Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Other hematologic neoplasm 3Lymphoid 3Thoracic 2Sarcoma 1Plasma cell 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 8Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Colorectal Neoplasms 2Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Amyloidosis 1

Interventions

Dexamethasone 109pomalidomide 53Cyclophosphamide 52Bortezomib 42fludarabine phosphate 33Lenalidomide 33Peripheral Blood Stem Cell Transplantation 28carfilzomib 26Mycophenolic Acid 25daratumumab 24Calcium Dobesilate 24Cyclosporine 22Busulfan 21Antilymphocyte Serum 20Tacrolimus 19Whole-Body Irradiation 18Melphalan 17Radiotherapy 15Filgrastim 15Methotrexate 14fludarabine 12Methylprednisolone 12elotuzumab 11Cord Blood Stem Cell Transplantation 11selinexor 10ixazomib 9Etoposide 8Thalidomide 7Prednisone 7Panobinostat 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Interleukin-2 × Plasma cell × Clear all
NCT04887259 2025-01-27

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Lava Therapeutics

Phase 1 Terminated
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡